Altomare, I., Russell, K. B., Uronis, H. E., Morse, M., Hsu, S. D., Zafar, Y., … Hurwitz, H. (2010). Phase II trial of bevacizumab (B) plus everolimus (E) for refractory metastatic colorectal cancer (mCRC). In Journal of Clinical Oncology (Vol. 28, pp. 3535–3535). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2010.28.15_suppl.3535

Altomare, I., K. B. Russell, H. E. Uronis, M. Morse, S. D. Hsu, Y. Zafar, J. C. Bendell, A. Starodub, W. Honeycutt, and H. Hurwitz. “Phase II trial of bevacizumab (B) plus everolimus (E) for refractory metastatic colorectal cancer (mCRC).” In Journal of Clinical Oncology, 28:3535–3535. American Society of Clinical Oncology (ASCO), 2010. https://doi.org/10.1200/jco.2010.28.15_suppl.3535.

Altomare I, Russell KB, Uronis HE, Morse M, Hsu SD, Zafar Y, et al. Phase II trial of bevacizumab (B) plus everolimus (E) for refractory metastatic colorectal cancer (mCRC). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010. p. 3535–3535.

Altomare, I., et al. “Phase II trial of bevacizumab (B) plus everolimus (E) for refractory metastatic colorectal cancer (mCRC).” Journal of Clinical Oncology, vol. 28, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2010, pp. 3535–3535. Crossref, doi:10.1200/jco.2010.28.15_suppl.3535.

Altomare I, Russell KB, Uronis HE, Morse M, Hsu SD, Zafar Y, Bendell JC, Starodub A, Honeycutt W, Hurwitz H. Phase II trial of bevacizumab (B) plus everolimus (E) for refractory metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010. p. 3535–3535.